Investment Rating - The report maintains a "Buy" rating for the company [6] Core Views - The company is expected to achieve a net profit of $13.4 to $14.8 million in H1 2025, representing a year-on-year growth of 538.1% to 604.8% [1] - The growth in net profit is primarily driven by a low base in H1 2024, continued growth in overseas markets, and lower investment and operating expenses [2] - The company has made a strategic investment in the orthodontic brand Shuyaki, acquiring a 35% stake to deepen its presence in emerging markets and enhance the penetration of invisible orthodontics [3] Financial Performance - The company’s revenue is projected to grow from $208 million in 2023 to $318 million in 2025, with year-on-year growth rates of 14.3% in 2023, 29.0% in 2024, and 18.1% in 2025 [5] - The net profit is expected to increase from $8 million in 2023 to $13 million in 2025, with growth rates of -75.4% in 2023, 60.4% in 2024, and 4.4% in 2025 [5] - The earnings per share (EPS) is forecasted to be $0.07 in 2025, with a price-to-earnings (P/E) ratio of 98.3 [5] Market Expansion - The company has established a localized development strategy, with significant growth in international cases, increasing from 33,000 in 2023 to 140,700 in 2024, a year-on-year increase of 326.4% [2] - The company is expanding its production capabilities in Brazil and is set to build a new manufacturing facility in Wisconsin, USA, which will be one of the most advanced centers for invisible orthodontics globally [2] Marketing Strategies - The company is actively enhancing its brand influence through diverse marketing strategies tailored to different city tiers, including collaborations with popular brands like My Little Pony and initiatives like the Angel KiD Star Plan [4]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1、朗姿股份有限公司（以下简称"朗姿股份"或"公司"）第五届董事会第二十九次会议和2024年度股东 大会分别审议通过了《关于2025年度对外担保额度的议案》，同意2025年度公司及其控股子公司的对外 担保总额不超过30.50亿元（以下除非特别注明，所称"元"均指"人民币元"），其中对资产负债率未超 过70%的控股子公司担保额度为24.00亿元，对资产负债率超过70%的控股子公司担保额度为6.50亿元。 该担保额度的有效期自公司2024年度股东大会审议批准本议案之日起至2025年度股东大会召开之日止。 截至本公告披露日，公司及控股子公司对外担保总余额为116,716万元，占公司2024年度经审计净资产 的41.87%；其中，实际被担保方北京莱茵服装有限公司资产负债率超过70%，公司对资产负债率超过 70%的控股子公司担保余额为1,000万元。 2、公司及其控股子公司对合并报表外单位提供的担保总余额为36,000万元，占公司2024年度经审计净 资产的12 ...

Core Viewpoint - The announcement details the approval of a guarantee framework for 2025, allowing the company and its subsidiaries to provide external guarantees totaling up to 3.05 billion RMB, with specific allocations based on the subsidiaries' debt ratios [2]. Summary by Sections 1. Guarantee Overview - The company has approved a total external guarantee limit of 3.05 billion RMB for 2025, with 2.4 billion RMB allocated for subsidiaries with a debt ratio not exceeding 70% and 650 million RMB for those exceeding 70% [2]. - As of the announcement date, the total external guarantee balance is 1.16716 billion RMB, representing 41.87% of the company's audited net assets for 2024 [2][14]. 2. Guarantee Details - The company provides a maximum joint liability guarantee of 160 million RMB for its subsidiary, Beijing Medical Management Co., Ltd. (Beijing Medical), which is borrowing from Hangzhou Bank [5]. - Beijing Medical also provides a joint liability guarantee for the company’s borrowing of 30 million RMB from Shanghai Pudong Development Bank [6]. 3. Financial Data - Beijing Medical has a registered capital of 1 billion RMB and was established on August 31, 2022 [8]. - The company has a registered capital of approximately 442.45 million RMB and was founded on November 9, 2006 [8]. 4. Guarantee Agreements - The guarantee for Beijing Medical's loan includes a maximum guarantee amount of 176 million RMB, covering all principal, interest, penalties, and related costs [9]. - The guarantee for the company's loan from Shanghai Pudong Development Bank has a maximum amount of 30 million RMB, covering similar costs as the previous agreement [10][11]. 5. Board Opinion - The board believes that the mutual guarantees between the company and its subsidiary will support business development and enhance operational stability without negatively impacting the company or its shareholders [12]. 6. Related Transactions - From January 1 to June 30, 2025, the company engaged in related transactions totaling approximately 54.62 million RMB with its actual controller and related parties [13]. 7. Guarantee Status - The company has no overdue guarantees or guarantees involved in litigation, ensuring a stable financial position [3][14].

Revenue Composition - In 2024, the revenue composition of Langzi Co., Ltd. is as follows: Medical Aesthetics accounts for 48.92%, Fashion Women's Wear accounts for 33.83%, Green Baby Products accounts for 16.19%, and Other Businesses account for 1.06% [1] Guarantee and Debt Information - As of the announcement date, the total guarantee amount for the company and its subsidiaries is 1.828 billion yuan, with an external guarantee balance of approximately 1.167 billion yuan, which represents 41.87% of the company's audited net assets for 2024 [3] - The actual guaranteed party, Beijing Rhine Clothing Co., Ltd., has a debt-to-asset ratio exceeding 70%, and the company has a guarantee balance of 10 million yuan for subsidiaries with a debt-to-asset ratio over 70% [3] - The total guarantee balance provided by the company and its subsidiaries to entities outside the consolidated financial statements is 360 million yuan, accounting for 12.92% of the company's audited net assets for 2024 [3]

证券之星消息，8月5日医疗美容板块较上一交易日上涨0.41%，锦波生物领涨。当日上证指数报收于 3617.6，上涨0.96%。深证成指报收于11106.96，上涨0.59%。医疗美容板块个股涨跌见下表： | 代码 | | | 名称 主力净流入（元） 主力净占比 游资净流入（元） 游资净占比 散户净点比 | | | | | --- | --- | --- | --- | --- | --- | --- | | 000615 *ST美谷 | 271.70万 | 17.26% | -314.88万 | -20.00% | 43.17万 | 2.74% | | 300896 爱美客 | -244.71万 | -0.61% | 2272.19万 | 5.64% | -2027.48万 | -5.04% | | 688363 华熙生物 | -618.47万 | -4.84% | 768.54万 | 6.01% | -150.07万 | -1.17% | 从资金流向上来看，当日医疗美容板块主力资金净流出591.48万元，游资资金净流入2725.85万元，散户 资金净流出2134.38万元。医疗美容板块个股资金流向见下表： ...

Group 1 - The stock price of Sichuan Shuangma closed at 19.33 yuan on August 4, 2025, with a slight decrease of 0.02 yuan, representing a drop of 0.10% [1] - The company reported a trading volume of 1.58 billion yuan, with a fluctuation of 1.91% and a turnover rate of 1.08% on the same day [1] - Sichuan Shuangma's main business includes cement and building materials, while also venturing into biotechnology and medical aesthetics [1] Group 2 - The company aims to continuously promote the development of its core business and focus on high-growth industries such as biotechnology [1] - Sichuan Shuangma is seeking synergistic business opportunities to enhance its long-term competitiveness [1] - In investor interactions, the company expressed its commitment to optimizing its business layout and enhancing investor confidence through performance growth and development prospects [1] Group 3 - On August 4, the net inflow of main funds was 3.6693 million yuan, with a cumulative net inflow of 22.8371 million yuan over the past five days [1]

证券之星消息，8月4日医疗美容板块较上一交易日下跌0.9%，*ST美谷领跌。当日上证指数报收于 3583.31，上涨0.66%。深证成指报收于11041.56，上涨0.46%。医疗美容板块个股涨跌见下表： 从资金流向上来看，当日医疗美容板块主力资金净流出5284.74万元，游资资金净流入2440.66万元，散户 资金净流入2844.08万元。医疗美容板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 183.25 | -0.69% | 2.05万 | 3.73 Z | | 832982 | 锦波生物 | 319.85 | -0.95% | 7186.67 | 2.30 Z | | 688363 | 华熙生物 | 51.35 | -1.15% | 2.85万 | 1.46 Z | | 000615 | *ST美谷 | 3.0 ...

Group 1 - The company Langzi Co., Ltd. (SZ 002612) announced on August 1 that its fifth board meeting was held to review the proposal for amending the company's basic management system [1] - For the fiscal year 2024, the revenue composition of Langzi Co., Ltd. is as follows: Medical Aesthetics accounts for 48.92%, Fashion Women's Wear accounts for 33.83%, Green Baby Products accounts for 16.19%, and Other Businesses account for 1.06% [1]

Industry Overview - The medical beauty industry in China has developed rapidly despite its late start, with a comprehensive industry chain that includes upstream raw material suppliers and medical equipment providers, midstream public and private institutions, and downstream consumers [1][2]. Key Players - Major upstream raw material manufacturers include Huaxi Biological, Aimeike, Haohai Biological, Huadong Pharmaceutical, and Jiao Dian Biological, while medical equipment is primarily supplied by foreign leading manufacturers [2]. - Midstream medical institutions consist of well-known entities such as Huahan Plastic Surgery, Lido Plastic Surgery, and Ruile Medical, along with emerging platforms like Xinyang and Gem [2]. Regional Distribution - The coastal regions of China have a dense distribution of representative enterprises in the medical beauty industry, with significant concentrations in Beijing, Shanghai, and Guangzhou, which are home to top research institutions and production companies [5]. - These regions attract numerous renowned medical beauty hospitals and clinics, providing comprehensive and high-quality services to consumers [5]. Business Layout of Representative Companies - Companies like Aimeike and Huaxi Biological focus on domestic sales, while others like Langzi and Huahan have diversified regional strategies across various provinces [7]. - Some companies specialize in product development, while others emphasize service delivery, with notable examples including Aimeike and Haohai focusing on product R&D, and Aoyuan Meigu's strong hospital brand image [7]. Financial Performance - Aimeike reported a medical beauty business revenue of 3.023 billion yuan, with a business proportion of 99.90%, indicating a strong focus on medical devices [8]. - Huadong Pharmaceutical generated 2.041 billion yuan from its medical beauty segment, accounting for 4.87% of its total business [9]. Investment Trends and Future Plans - Companies are actively expanding their business layouts with a trend towards diversification and internationalization, such as Aimeike's acquisition of a Korean company and Haohai's collaboration with a U.S. firm for product innovation [10][11]. - Huadong Pharmaceutical is expanding its medical beauty business through acquisitions and partnerships, while Huaxi Biological is investing in new technologies and products [10][11].

Core Points - From January 1, 2026, foreign tourists in South Korea will no longer be able to apply for tax refunds on medical beauty services, as the government has decided not to extend the special VAT refund policy for foreign tourists, which will officially expire on December 31 of this year [1] - The South Korean government implemented a temporary VAT refund policy for medical beauty services in April 2016 to promote high-value medical tourism related to the Korean Wave, allowing foreign tourists to claim a 10% VAT refund when receiving services at designated medical institutions [1] - In 2024, it is estimated that 1.17 million foreign patients will visit South Korea for medical treatment, with a total medical expenditure of 1.41 trillion KRW, averaging about 1.53 million KRW per person [1] - The medical beauty tax refund applications have reached 1.01 million, with a total refund amount of 95.5 billion KRW [1] - The medical and tourism industries in South Korea are calling for the government to extend the tax refund policy, as the "cost-performance" advantage of the medical beauty industry is seen as a core competitive strength to attract foreign visitors [1] Industry Concerns - There are concerns that the lack of institutional incentives may lead some institutions and customers to evade taxes through cash transactions, resulting in regulatory difficulties and transparency issues [2] - The Ministry of Health and Welfare plans to negotiate with tax authorities to seek an extension of the temporary policy, leaving room for potential adjustments [2]